OBJECTIVE： To observe the clinical efficacy and safety of recombinant human endostatin （rh-endostatin） combined with Lobaplatin for injection and irinotecan injection in the treatment of advanced recurrent small cell lung cancer （SCLC）. METHODS： A total of 88 patients with advanced recurrent SCLC in our hospital were divided into control group （41 cases） and observation group （47 cases） according to random number table. Control group was given Irinotecan injection+Lobaplatin for injection. Observation group was additionally given Recombinart human endostatin injection 15 mg added into 0.9％ Sodium chloride injection 250 mL， ivgtt， qd， for consecutive 14 d， every 14 d. A treatment course lasted for 28 d， and both groups were treated for 2 courses.  The clinical efficacy， the levels of serum carcinoembryonic antigen （CEA）， the scores physical state （ECOG） and quality of life （QOL） before， after treatment were observed in the two groups， and the survival and adverse reactions of the two groups were compared. RESULTS： The total response rate of observation group was 59.6％， which was higher than 43.9％ of control group， but there was no statistical significance （P＞0.05）. Before treatment，  there was no significant difference in serum CEA levels， ECOG scores or QOL scores，between 2 groups （P＞0.05）； after treatment， the serum CEA levels of the two groups were significantly decreased， and the observation group was significantly lower than the control group， with statistically significant （P＜0.05）. In observation group， ECOG scores decreased while QOL scores increased significantly， and significantly better than the control group， with statistical significance （P＜0.05）.  The overall survival （OS） of observation group was 16.8 months， which was significantly higher than 11.5 months of control group， with statistical significance （P＜0.05）. The incidence of leucopenia in observation group was significantly higher than control group； the incidence of leucopenia and abnormal liver function were significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS： Rh-endostatin injection combined with lobaplatin and irinotecan can improve serum CEA levels and the quality of living aswell as prolong the survival time.